HC Wainwright & Co. Maintains Buy on Kyntra Bio, Lowers Price Target to $18
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
HC Wainwright & Co. analyst Matthew Keller maintains Kyntra Bio (NASDAQ:KYNB) with a Buy and lowers the price target from $43 to $18.
HC Wainwright & Co. analyst Matthew Keller maintains Kyntra Bio (NASDAQ:KYNB) with a Buy and lowers the price target from $43 to $18.
